---
title: "Genmab A/S (0MGB) Gets a Buy from Barclays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/291630946.md"
description: "Barclays analyst James Gordon maintained a Buy rating on Genmab A/S (0MGB) with a DKK2,500 price target. This follows Bank of America Securities' June 30 report, which also upheld a Buy rating and the same price target for the healthcare stock."
datetime: "2026-07-03T06:16:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/291630946.md)
  - [en](https://longbridge.com/en/news/291630946.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/291630946.md)
generator: "portal-rs"
---

# Genmab A/S (0MGB) Gets a Buy from Barclays

Barclays analyst James Gordon CFA maintained a Buy rating on Genmab A/S today and set a price target of DKK2,500.00.

### 4th of July Sale - 70% Off

-   Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
-   Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.

According to TipRanks, Gordon CFA is a 4-star analyst with an average return of 8.2% and a 69.57% success rate. Gordon CFA covers the Healthcare sector, focusing on stocks such as Galderma Group AG, GlaxoSmithKline, and AstraZeneca.

In a report released on June 30, Bank of America Securities also maintained a Buy rating on the stock with a DKK2,500.00 price target.

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [BAC.US](https://longbridge.com/en/quote/BAC.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [BAC-Q.US](https://longbridge.com/en/quote/BAC-Q.US.md)
- [BML-L.US](https://longbridge.com/en/quote/BML-L.US.md)
- [BAC-L.US](https://longbridge.com/en/quote/BAC-L.US.md)
- [BAC-K.US](https://longbridge.com/en/quote/BAC-K.US.md)
- [BML-H.US](https://longbridge.com/en/quote/BML-H.US.md)
- [BAC-N.US](https://longbridge.com/en/quote/BAC-N.US.md)
- [BAC-E.US](https://longbridge.com/en/quote/BAC-E.US.md)
- [MER-K.US](https://longbridge.com/en/quote/MER-K.US.md)
- [BAC-O.US](https://longbridge.com/en/quote/BAC-O.US.md)
- [BML-G.US](https://longbridge.com/en/quote/BML-G.US.md)
- [BAC-M.US](https://longbridge.com/en/quote/BAC-M.US.md)
- [BAC-B.US](https://longbridge.com/en/quote/BAC-B.US.md)
- [BML-J.US](https://longbridge.com/en/quote/BML-J.US.md)
- [BAC-S.US](https://longbridge.com/en/quote/BAC-S.US.md)
- [BAC-P.US](https://longbridge.com/en/quote/BAC-P.US.md)
- [8648.JP](https://longbridge.com/en/quote/8648.JP.md)

## Related News & Research

- [Genmab Updates Articles of Association, Expands Capital-Raising Flexibility](https://longbridge.com/en/news/295678408.md)
- [Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)](https://longbridge.com/en/news/295329030.md)
- [Septerna, Inc. (SEPN) Receives a Rating Update from a Top Analyst](https://longbridge.com/en/news/296029142.md)
- [Capital Increase in Genmab as a Result of Employee Warrant Exercise](https://longbridge.com/en/news/295566458.md)
- [Genmab’s Earnings Call Highlights Growth, Upgraded Outlook](https://longbridge.com/en/news/295165401.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**